Travere Therapeutics (TVTX) News Today → LEAKED: Jeff Bezos' $330 Million Gamble (From Behind the Markets) (Ad) Free TVTX Stock Alerts $7.42 +0.40 (+5.70%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 5:14 AM | marketbeat.comJump Financial LLC Sells 169,501 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Jump Financial LLC lowered its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 89.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,424 shares of the company's stMay 28, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Up 8.9%Travere Therapeutics (NASDAQ:TVTX) Stock Price Up 8.9%May 24, 2024 | marketbeat.comPanagora Asset Management Inc. Reduces Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Panagora Asset Management Inc. trimmed its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 66.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,909 shares of the company's stock afterMay 21, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Price Up 7.1%Travere Therapeutics (NASDAQ:TVTX) Trading 7.1% HigherMay 19, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and nine have given a buy rating to theMay 16, 2024 | markets.businessinsider.comBuy Rating on Travere Therapeutics: Filspari’s Market Potential and Positive Financial OutlookMay 15, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Trading Up 5.4%Travere Therapeutics (NASDAQ:TVTX) Trading Up 5.4%May 15, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX)Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings estimates for Travere Therapeutics in a report issued on Tuesday, May 7th. HC Wainwright analyst E. Arce now expects that the company will earn $0.13 per share for the year, down fromMay 9, 2024 | globenewswire.comTravere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressMay 8, 2024 | finance.yahoo.comLoss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-TermMay 8, 2024 | sfgate.comGossamer Bio: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Strong Filspari Sales and Favorable Regulatory ProspectsMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Travere Therapeutics (TVTX)May 7, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $19.00 target price on shares of Travere Therapeutics in a research note on Tuesday.May 7, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Up Following Analyst UpgradeTravere Therapeutics (NASDAQ:TVTX) Shares Gap Up on Analyst UpgradeMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Robust Drug Sales and Promising Market ExpansionMay 7, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)May 7, 2024 | msn.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Price Target Increased to $18.00 by Analysts at Canaccord Genuity GroupCanaccord Genuity Group boosted their price target on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday.May 7, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Announces Quarterly Earnings ResultsTravere Therapeutics (NASDAQ:TVTX - Get Free Report) released its quarterly earnings data on Monday. The company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.78). Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. The business had revenue of $41.40 million for the quarter, compared to the consensus estimate of $43.46 million. During the same quarter last year, the business earned ($1.27) EPS. Travere Therapeutics's revenue for the quarter was up 34.0% compared to the same quarter last year.May 7, 2024 | finance.yahoo.comTravere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...May 6, 2024 | finance.yahoo.comTravere Therapeutics Reports Q1 2024 Results: A Mixed Financial Performance Amidst Strategic ...May 6, 2024 | msn.comTVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024May 6, 2024 | finance.yahoo.comTravere Therapeutics Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comTravere Therapeutics Reports First Quarter 2024 Financial ResultsMay 5, 2024 | msn.comTravere Therapeutics Q1 2024 Earnings PreviewApril 30, 2024 | marketbeat.comTravere Therapeutics (TVTX) Scheduled to Post Earnings on MondayTravere Therapeutics (NASDAQ:TVTX) will be releasing earnings after the market closes on Monday, May 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=368782)April 29, 2024 | globenewswire.comTravere Therapeutics to Report First Quarter 2024 Financial ResultsApril 26, 2024 | marketbeat.comTravere Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.80) Per Share (NASDAQ:TVTX)Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Investment analysts at HC Wainwright cut their FY2025 EPS estimates for shares of Travere Therapeutics in a report issued on Wednesday, April 24th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings of ($1.80)April 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US ProspectsApril 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue ProjectionsApril 25, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Post FY2028 Earnings of $4.29 Per ShareTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - HC Wainwright lowered their FY2028 earnings estimates for Travere Therapeutics in a note issued to investors on Wednesday, April 24th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of $4.29 for thApril 24, 2024 | markets.businessinsider.comFILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere TherapeuticsApril 24, 2024 | marketbeat.comHC Wainwright Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $19.00HC Wainwright lifted their price objective on shares of Travere Therapeutics from $17.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday.April 24, 2024 | globenewswire.comTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 24, 2024 | prnewswire.comCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyApril 19, 2024 | marketbeat.comVontobel Holding Ltd. Purchases Shares of 287,423 Travere Therapeutics, Inc. (NASDAQ:TVTX)Vontobel Holding Ltd. purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 287,423 shares of the company's stock, valued at approximately $2,5April 17, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Earns "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and set a $13.00 price objective on shares of Travere Therapeutics in a research note on Wednesday.April 14, 2024 | investing.comTravere Therapeutics CFO sells shares to cover tax obligationsApril 10, 2024 | marketbeat.comVanguard Group Inc. Acquires 460,176 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)Vanguard Group Inc. raised its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 10.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,667,458 shares of the company's stock after buying an additionalApril 4, 2024 | nz.finance.yahoo.comStock market today: Stocks slide after Fedspeak as oil surges, March jobs report on deckApril 4, 2024 | globenewswire.comTravere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalApril 3, 2024 | globenewswire.comTravere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationApril 1, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Trading Down 6%Travere Therapeutics (NASDAQ:TVTX) Trading Down 6%March 27, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down to $7.57Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down to $7.57March 27, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Receives "Neutral" Rating from GuggenheimGuggenheim reaffirmed a "neutral" rating on shares of Travere Therapeutics in a report on Wednesday.March 21, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Trading 7.5% Higher Travere Therapeutics (NASDAQ:TVTX) Shares Up 7.5%March 13, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlook Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address On June 10, Nvidia makes its next big move (Ad)A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.” Click here to find out who they are. TVTX Media Mentions By Week TVTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼1.430.78▲Average Medical News Sentiment TVTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼33▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Harrow News Today Omeros News Today Rigel Pharmaceuticals News Today Catalyst Pharmaceuticals News Today Galapagos News Today Agios Pharmaceuticals News Today Protagonist Therapeutics News Today Zai Lab News Today Keros Therapeutics News Today Structure Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
